The estimated prevalence of PD-L1 expression in patients with gastroesophageal adenocarcinomas ranges between 40% and 57%, as reported, respectively, in KEYNOTE-012 and KEYNOTE-059, both early phase trials to evaluate the safety of pembrolizumab in patients with gastric cancer [35,36]. This evidence concerns the gene CD274 and gastric cancer.